Dear customer, upon your request Imfinzi Company were found the following resources. Our team makes effort to make you happy with the search on our site ninan.org

Imfinzi is first immunotherapy to show both significant ...

Sep 09, 2019 · Imfinzi (durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses. Imfinzi is also approved for previously-treated patients with advanced bladder cancer in 10 countries, including the US.…

Imfinzi significantly reduces the risk of disease ...

May 12, 2017 · Imfinzi met a primary endpoint of statistically-significant and clinically-meaningful progression-free survival (PFS) in ‘all-comer’ patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer in a planned interim analysis Imfinzi is the first immuno-oncology medicine to show superior PFS in this setting…

Imfinzi (durvalumab) FDA Approval History - Drugs.com

Imfinzi (durvalumab) is an anti-PD-L1 (programmed death ligand-1) human monoclonal antibody for the treatment of patients with metastatic urothelial carcinoma and for the treatment of patients with unresectable non-small cell lung cancer that has not progressed after chemoradiation. Development History and FDA Approval Process for Imfinzi…

How IMFINZI® (durvalumab) Works

IMFINZI is a medicine that may treat a type of lung cancer by working with your immune system. In some patients, IMFINZI can cause the immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.…